[go: up one dir, main page]

AR110728A1 - Terapia combinada para el tratamiento del cáncer - Google Patents

Terapia combinada para el tratamiento del cáncer

Info

Publication number
AR110728A1
AR110728A1 ARP180100028A ARP180100028A AR110728A1 AR 110728 A1 AR110728 A1 AR 110728A1 AR P180100028 A ARP180100028 A AR P180100028A AR P180100028 A ARP180100028 A AR P180100028A AR 110728 A1 AR110728 A1 AR 110728A1
Authority
AR
Argentina
Prior art keywords
cancer
formula
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
ARP180100028A
Other languages
English (en)
Inventor
Debra A Tonetti
Jiong Zhao
Rui Xiong
Gregory R Thatcher
Jay C Strum
Original Assignee
G1 Therapeutics Inc
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G1 Therapeutics Inc, Univ Illinois filed Critical G1 Therapeutics Inc
Publication of AR110728A1 publication Critical patent/AR110728A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones, combinaciones y métodos que comprenden la administración de un inhibidor de CDK4/6 de la fórmula D con un regulador negativo de la expresión selectivo del receptor de estrógeno de la fórmula A, B o C, que ofrecen ventajas en el tratamiento de una proliferación celular anormal, incluido un cáncer o un tumor. Reivindicación 1: Una combinación farmacéutica para tratar un cáncer o un tumor en un sujeto caracterizada porque incluye una cantidad terapéuticamente eficaz en una o más formas de dosificación separadas de un compuesto de fórmula A con una cantidad terapéuticamente eficaz de un compuesto de fórmula D, en donde la fórmula A se selecciona entre los compuestos de fórmulas (1), (2) y (3), o una sal farmacéuticamente aceptable del mismo, y en donde fórmula D es un compuesto seleccionado entre los compuestos de fórmulas (4), (5), (6) y (7), o una sal farmacéuticamente aceptable del mismo. Reivindicación 3: La combinación de la reivindicación 2, caracterizada porque el cáncer es cáncer de mama, cáncer de ovario, cáncer de endometrio, cáncer de riñón, cáncer de útero, cáncer de próstata, o cáncer de pulmón. Reivindicación 20: La combinación de cualquiera de las reivindicaciones 1 - 19, caracterizada porque la fórmula A es un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo.
ARP180100028A 2017-01-06 2018-01-05 Terapia combinada para el tratamiento del cáncer AR110728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762443588P 2017-01-06 2017-01-06

Publications (1)

Publication Number Publication Date
AR110728A1 true AR110728A1 (es) 2019-04-24

Family

ID=62791140

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100028A AR110728A1 (es) 2017-01-06 2018-01-05 Terapia combinada para el tratamiento del cáncer

Country Status (15)

Country Link
US (1) US11364222B2 (es)
EP (1) EP3565558B1 (es)
JP (1) JP7229162B2 (es)
KR (1) KR102576011B1 (es)
CN (1) CN110177554B (es)
AR (1) AR110728A1 (es)
AU (2) AU2018205262A1 (es)
CA (1) CA3048057A1 (es)
EA (1) EA201991622A1 (es)
IL (1) IL267795B2 (es)
MX (1) MX2019008158A (es)
NZ (1) NZ754865A (es)
TW (1) TWI823845B (es)
WO (1) WO2018129387A1 (es)
ZA (1) ZA201904188B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038180B1 (ru) 2015-12-09 2021-07-20 Зе Боард Оф Трастис Оф Зе Юниверсити Оф Иллинойс Бензотиофеновые селективные понижающие регуляторы эстрогеновых рецепторов
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
EP3709997A1 (en) 2017-11-16 2020-09-23 Novartis AG Pharmaceutical combination comprising lsz102 and ribociclib
WO2019099036A1 (en) 2017-11-17 2019-05-23 Convergascent Llc Devices and systems for intraluminal local drug delivery
US12017022B2 (en) 2017-11-17 2024-06-25 Isola Therapeutics, Inc. Devices and systems for intraluminal local drug delivery
EP3716969A1 (en) 2017-12-01 2020-10-07 Novartis AG Pharmaceutical combination comprising lsz102 and alpelisib
DK3820874T3 (da) * 2018-07-12 2022-12-12 Lilly Co Eli Selektive estrogenreceptornedbrydere
TW202022124A (zh) 2018-08-17 2020-06-16 瑞士商赫孚孟拉羅股份公司 用於治療乳癌的診斷及治療方法
JP2022506829A (ja) * 2018-11-09 2022-01-17 ジー1、セラピューティクス、インコーポレイテッド エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン
CN112840402B (zh) * 2019-09-02 2024-05-07 北京哲源科技有限责任公司 获得细胞内确定性事件的方法及电子设备
EP4096686A4 (en) * 2020-01-27 2024-01-10 Isola Therapeutics, Inc. TISSUE DOSAGE FOR LOCAL INTRALUMINAL DRUG ADMINISTRATION
AU2021273744A1 (en) 2020-05-19 2022-12-08 G1 Therapeutics, Inc. Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
CN117222411A (zh) * 2021-03-24 2023-12-12 贝达药业股份有限公司 药物组合、包含其的试剂盒及其用途

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE4126999A1 (de) 1991-08-16 1993-02-18 Basf Ag Herbizide mittel, enthaltend 3-aminobenzo(b)thiophene als antidots
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
CZ285937B6 (cs) 1992-01-16 1999-12-15 Hoechst Aktiengesellschaft Arylcykloalkylové deriváty, způsob přípravy těchto derivátů a jejich použití
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
EP0622673B1 (en) 1993-04-24 1998-02-04 Kodak Limited Photographic colour couplers and photographic materials containing them
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5834468A (en) 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
AU749750B2 (en) 1997-02-05 2002-07-04 Warner-Lambert Company Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
WO1999018101A1 (en) 1997-10-03 1999-04-15 Eli Lilly And Company Benzothiophenes
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
CA2412560C (en) 2000-06-26 2008-12-30 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
WO2002003990A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
CA2414060A1 (en) 2000-07-06 2002-01-17 Wyeth Combinations of statins, estrogenic agents and optionally estrogens
JP2004502730A (ja) 2000-07-06 2004-01-29 ワイス ビスホスホネート、エストロゲン剤および所望によるエストロゲンの組み合わせ
WO2002003975A2 (en) 2000-07-06 2002-01-17 Wyeth Combinations of ssri and estrogenic agents
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
US20020016318A1 (en) 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
WO2002003988A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
CA2414111A1 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
DE60106281T2 (de) 2000-08-11 2005-02-24 Wyeth Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
CA2473026C (en) 2002-01-22 2011-05-03 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2004009603A1 (en) 2002-07-24 2004-01-29 Eli Lilly And Company Dihydro-dibenzo[b,e]oxepine based selective estrogen receptor modulators, compositions and methods
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
MXPA06000484A (es) 2003-07-11 2006-04-05 Warner Lambert Co Sal de isetionato de un inhibidor selectivo de la quinasa 4 dependiente de ciclina.
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ(muri)の阻害剤としての縮合複素環
RU2006117368A (ru) 2003-10-23 2007-12-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные триазаспиропипередина, предназначенные для применения в качестве ингибиторов glyt-1 при лечении неврологических и психоневрологических нарушений
JP2005129430A (ja) 2003-10-27 2005-05-19 Konica Minolta Holdings Inc 光電変換材料用半導体、光電変換素子及び太陽電池
FR2862646B1 (fr) 2003-11-20 2006-02-24 Merck Sante Sas Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
AU2004299286B2 (en) 2003-12-15 2011-06-30 Laboratoire Theramex 1-N-phenyl-amino-1H-imidazole derivatives and pharmaceutical compositions containing them
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
WO2006074985A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
CA2595477A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
WO2006084338A1 (en) 2005-02-14 2006-08-17 Bionomics Limited Novel tubulin polymerisation inhibitors
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
CA2640678C (en) 2006-02-03 2015-03-31 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EP1947085A1 (en) 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
AU2008268442A1 (en) 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
KR20100027231A (ko) 2007-07-25 2010-03-10 에프. 호프만-라 로슈 아게 벤조퓨란- 및 벤조[b]티오펜-2-카복실산 아마이드 유도체 및 이의 히스타민 3 수용체 조절제로서의 용도
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
CA2709202C (en) 2007-12-19 2013-04-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
ES2964764T3 (es) 2008-07-29 2024-04-09 Nerviano Medical Sciences Srl Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino
JP5560496B2 (ja) 2008-08-22 2014-07-30 ノバルティス アーゲー Cdk阻害剤としてのピロロピリミジン化合物
CN102231983A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
CN102231984A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
WO2010093578A1 (en) 2009-02-10 2010-08-19 Glaxo Group Limited Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
US8809382B2 (en) 2009-05-04 2014-08-19 The Royal Institution For The Advancement Of Learning/Mcgill University 5-oxo-ETE receptor antagonist compounds
WO2010132725A2 (en) 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
BR112012027745A2 (pt) 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia
DK2580210T5 (en) 2010-06-10 2017-06-19 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
JP5844376B2 (ja) 2010-10-06 2016-01-13 ジェイファーマ株式会社 強力な尿酸トランスポーター阻害剤の開発:それらの尿酸排泄効果のために設計された化合物
CN104045654A (zh) 2010-10-25 2014-09-17 G1治疗公司 Cdk抑制剂
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
JP5886873B2 (ja) 2010-12-24 2016-03-16 メルク・シャープ・エンド・ドーム・ベー・フェー N置換アゼチジン誘導体
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
KR20140101399A (ko) 2011-12-14 2014-08-19 세라곤 파마슈티컬스, 인크. 불화 에스트로겐 수용체 조절제 및 이의 용도
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
US20140378422A1 (en) 2012-01-31 2014-12-25 Novartis Ag Combination of a RTK inhibitor with an anti-estrogen and use thereof for the treatment of cancer
NZ630124A (en) 2012-03-20 2016-01-29 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
US10202392B2 (en) 2012-04-26 2019-02-12 Francis Xavier Tavares Synthesis of lactams
EP2892826A1 (en) 2012-09-05 2015-07-15 Koninklijke Philips N.V. Capsule for the preparation of beverages, device and method
CA2928173C (en) 2012-10-24 2021-10-19 The Board Of Trustees Of The University Of Illinois Compositions comprising benzothiophene derivatives and use thereof for treatment of estrogen-related medical disorders
WO2014066695A1 (en) 2012-10-24 2014-05-01 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating estrogen-related medical disorders
ES2671516T3 (es) 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
RU2015138964A (ru) 2013-03-14 2017-04-18 Серагон Фармасьютикалз, Инк. Полициклические модуляторы рецептора эстрогена и их применения
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
CN107417691B (zh) * 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
US20140274896A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
EP3004090B1 (en) 2013-05-28 2017-10-25 Astrazeneca AB Chemical compounds
SG11201509508YA (en) 2013-06-19 2015-12-30 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof
RU2015152171A (ru) 2013-06-19 2017-07-25 Серагон Фармасьютикалз, Инк. Азетидиновые модуляторы эстрогеновых рецепторов и их применения
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2015061407A1 (en) 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
US9855270B2 (en) 2014-03-13 2018-01-02 Genentech, Inc. Methods and compositions for modulating estrogen receptor mutants
US20150258080A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic combinations with estrogen receptor modulators
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
US20150297607A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
US20160020862A1 (en) * 2014-07-17 2016-01-21 Qualcomm Incorporated Impedance tuning for a power amplifier load tuner, a receive tuner, and an antenna tuner
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
EP3303326B1 (en) 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
JP2018521988A (ja) 2015-06-16 2018-08-09 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. ピペリジン誘導体およびその製造方法および医薬用途
PL3355884T3 (pl) 2015-10-01 2021-11-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pirydo[3,4-b]indolowe leki antyestrogenowe
WO2017056115A1 (en) 2015-10-03 2017-04-06 Sun Pharma Advanced Research Company Limited Novel n-aryl containing fused heterocyclic compounds
US9975856B2 (en) 2015-10-07 2018-05-22 Genentech, Inc. Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
IL283559B (en) 2015-10-27 2022-07-01 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens
JP6920295B2 (ja) 2015-11-09 2021-08-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
CN107428758B (zh) 2015-11-12 2020-08-04 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途
EA038180B1 (ru) 2015-12-09 2021-07-20 Зе Боард Оф Трастис Оф Зе Юниверсити Оф Иллинойс Бензотиофеновые селективные понижающие регуляторы эстрогеновых рецепторов
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
CN109789142B (zh) 2016-07-01 2022-08-23 G1治疗公司 N-(杂芳基)-吡咯并[3,2-d]嘧啶-2-胺的合成
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018005860A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
AU2017372856B9 (en) 2016-12-05 2024-01-04 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
IL271543B2 (en) 2017-06-29 2025-01-01 G1 Therapeutics Inc Morphological forms of G1T38 and methods for their production
EP3735247A1 (en) 2018-01-04 2020-11-11 G1 Therapeutics, Inc. Heterocyclic compounds for the treatment of abnormal cellular proliferation
JP2021509680A (ja) 2018-01-08 2021-04-01 ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. G1t38の優れた投与レジメン
CN112218634A (zh) 2018-04-09 2021-01-12 G1治疗公司 具有驱动致癌突变的癌症的治疗
CA3109385A1 (en) 2018-08-16 2020-02-20 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators to treat medical disorders
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
JP2022506829A (ja) 2018-11-09 2022-01-17 ジー1、セラピューティクス、インコーポレイテッド エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Also Published As

Publication number Publication date
EP3565558A4 (en) 2020-08-26
JP7229162B2 (ja) 2023-02-27
WO2018129387A1 (en) 2018-07-12
NZ754865A (en) 2023-07-28
US20190321332A1 (en) 2019-10-24
CN110177554B (zh) 2023-06-02
CA3048057A1 (en) 2018-07-12
IL267795A (en) 2019-09-26
EA201991622A1 (ru) 2020-01-23
AU2022203554B2 (en) 2024-03-28
AU2022203554A1 (en) 2022-06-16
TW201836600A (zh) 2018-10-16
KR20190103285A (ko) 2019-09-04
IL267795B (en) 2022-10-01
RU2019124081A3 (es) 2022-01-31
KR102576011B1 (ko) 2023-09-06
TWI823845B (zh) 2023-12-01
EP3565558B1 (en) 2023-12-06
EP3565558A1 (en) 2019-11-13
BR112019013814A2 (pt) 2020-01-21
MX2019008158A (es) 2019-12-09
JP2020514292A (ja) 2020-05-21
ZA201904188B (en) 2022-12-21
US11364222B2 (en) 2022-06-21
CN110177554A (zh) 2019-08-27
RU2019124081A (ru) 2021-02-08
AU2018205262A1 (en) 2019-07-11
IL267795B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
AR110728A1 (es) Terapia combinada para el tratamiento del cáncer
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
AR108202A1 (es) Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1
MX2021003389A (es) Metodos para tratar el cancer.
MX2020011868A (es) Inhibidores de los receptores erbb.
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
MX2020003666A (es) Compuestos y composiciones para el tratamiento de trastornos hematologicos.
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
CL2021001027A1 (es) Inhibidores selectivos de rgmc y el uso de los mismos
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
MX2021010321A (es) Compuestos macrociclicos.
AR112103A1 (es) Compuestos para el tratamiento de tnbc
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
ECSP20084330A (es) Activadores de la respuesta a proteínas desplegadas
MX2019011743A (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres.
CO2020013968A2 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer
CU20190042A7 (es) Compuestos derivados de naftiridinona